The anonymous survey is open to anyone 18 or over who has taken ibogaine at least once and is fluent in English.
The Ohio State University’s Center for Psychedelic Drug Research and Education recently initiated a global survey asking participants to share their experiences with ibogaine treatment for addiction, PTSD, traumatic brain injury and other conditions.
The Global Ibogaine Patient Survey is “the first large-scale international study collecting real-world evidence on the safety and effectiveness of ibogaine treatment,” according to the center.
Dr. Alan Davis, director of OSU’s Center for Psychedelic Drug Research and Education, is leading the research, which aims to gather comprehensive data from thousands of individuals who have received ibogaine treatment.
“With an estimated 10,000 people worldwide having undergone ibogaine treatment, this research addresses a critical knowledge gap in our understanding of alternative approaches to treating some of our most challenging health conditions,” Davis said in a news release. “This survey represents a unique opportunity for patients to contribute their experiences to science and potentially help shape future research and treatment approaches.”
The anonymous online survey will investigate:
- Patient demographics and treatment details
- Acute and enduring effects of ibogaine
- Therapeutic effects on substance withdrawal, cravings and use
- Effects on PTSD, TBI and other mental-health conditions
- Safety concerns and adverse events
- Personal meaning of the ibogaine experience
The center noted that the survey takes approximately 20 to 30 minutes to complete, and is open to anyone 18 or older who has taken ibogaine at least once in their lifetime and is fluent in English.
“The data from this global survey will help establish evidence-based protocols for screening, administration and aftercare, while potentially influencing regulatory decisions about ibogaine’s future as a medical treatment,” said Dr. Stacey Armstrong, co-investigator on the study. “This patient survey represents an important step toward understanding the real-world applications and limitations of ibogaine.”
Ibogaine in the Spotlight
The survey comes at a time when ibogaine is in the spotlight, as state and federal policymakers reconsider its potential therapeutic value.
The Texas Ibogaine Initiative – Texas House Bill 3717 and Senate Bill 2308 – is a 2025 legislative effort led by Texas state Rep. Cody Harris to secure $50 million in funding for research into ibogaine-assisted therapy for U.S. military veterans suffering from opioid-use disorder and other mental-health conditions.
Recent studies suggest ibogaine might be effective in reducing withdrawal symptoms and drug cravings while promoting neuroplasticity.
A 2024 Stanford University study found ibogaine treatment was associated with significant improvements in cognitive function, emotional regulation and reductions in PTSD and TBI symptoms among Special Operations veterans.